142128-57-2 | Levoketoconazole

Chemical type

• Steroidogenesis inhibitor

^[1]

• Steroidogenesis inhibitor (2S,4R enantiomer of ketoconazole)

^[2]

Key properties

• Similar to ketoconazole, blocks multiple enzymes in adrenal steroidogenesis
• Potential hepatotoxicity and drug interactions

^[1]

• Inhibits cortisol synthesis
• Treats endogenous hypercortisolemia
• Associated with weight loss (e.g., 1.8 kg in 8 weeks, 5.1 kg in 6 months in clinical trials)
• Normalizes cortisol levels
• May cause tiredness and slight blood pressure drop

^[2]

• Medical therapy for Cushing syndrome

^[1]

• Treatment of Cushing’s syndrome in adults where surgery is not an option or ineffective
• Adjunct for mild hypercortisolism of unknown origin
• Combination therapy with GLP-1 agonists for enhanced weight loss

^[2]

Classification by use

• Medications for Cushing syndrome
• Steroidogenesis inhibitors

^[1]

• Medications used for hypercortisolism management
• Endocrine disorder treatments

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Osilodrostat for Cyclic Cushing Disease, AACE Endocrinology and Diabetes, Volume 13, Issue 1, January–February 2026, Pages 17-21
2. [Cite:2] Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism, AACE Endocrinology and Diabetes, Volume 12, Issue 3, September–October 2025, Pages 146-149